Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (DE:22UA)
XETRA:22UA
Total Valuation
BioNTech SE has a market cap or net worth of €19.80B. The enterprise value is €12.27B.
Market Cap€19.80B
Enterprise Value€12.27B
Share Statistics
BioNTech SE has 252,531,940 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding252,531,940
Owned by Insiders0.35%
Owned by Institutions10.21%
Financial Efficiency
BioNTech SE’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -3.14%.
Return on Equity (ROE)-0.06
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)-3.14%
Return on Capital Employed (ROCE)-0.03
Revenue Per Employee407.06K
Profits Per Employee-161.14K
Employee Count6,772
Asset Turnover0.13
Inventory Turnover5.57
Valuation Ratios
The current PE Ratio of BioNTech SE is ―. BioNTech SE’s PEG ratio is -0.29.
PE Ratio―
PS Ratio7.10
PB Ratio1.02
Price to Fair Value1.02
Price to FCF72.58
Price to Operating Cash Flow36.98
PEG Ratio-0.29
Income Statement
In the last 12 months, BioNTech SE had revenue of 2.76B and earned -1.09B in profits. Earnings per share was -4.51.
Revenue2.76B
Gross Profit2.14B
Operating Income-623.87M
Pretax Income-1.01B
Net Income-1.09B
EBITDA-256.17M
Earnings Per Share (EPS)-4.51
Cash Flow
In the last 12 months, operating cash flow was 464.25M and capital expenditures -187.60M, giving a free cash flow of 276.65M billion.
Operating Cash Flow464.25M
Free Cash Flow276.65M
Free Cash Flow per Share1.10
Dividends & Yields
BioNTech SE pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.92
52-Week Price Change-14.81%
50-Day Moving Average90.51
200-Day Moving Average89.73
Relative Strength Index (RSI)40.33
Average Volume (3m)94.33K
Important Dates
BioNTech SE upcoming earnings date is May 11, 2026, Before Open (Confirmed).
Last Earnings DateMar 10, 2026
Next Earnings DateMay 11, 2026
Ex-Dividend Date―
Financial Position
BioNTech SE as a current ratio of 7.54, with Debt / Equity ratio of 1.39%
Current Ratio7.54
Quick Ratio7.49
Debt to Market Cap<0.01
Net Debt to EBITDA28.91
Interest Coverage Ratio-45.74
Taxes
In the past 12 months, BioNTech SE has paid 81.93M in taxes.
Income Tax81.93M
Effective Tax Rate-0.08
Enterprise Valuation
BioNTech SE EV to EBITDA ratio is -47.54, with an EV/FCF ratio of 45.14.
EV to Sales4.42
EV to EBITDA-47.54
EV to Free Cash Flow45.14
EV to Operating Cash Flow27.81
Balance Sheet
BioNTech SE has €14.83B in cash and marketable securities with €267.29M in debt, giving a net cash position of €14.57B billion.
Cash & Marketable Securities€14.83B
Total Debt€267.29M
Net Cash€14.57B
Net Cash Per Share€57.68
Tangible Book Value Per Share€71.34
Margins
Gross margin is 77.68%, with operating margin of -22.63%, and net profit margin of -39.59%.
Gross Margin77.68%
Operating Margin-22.63%
Pretax Margin-36.61%
Net Profit Margin-39.59%
EBITDA Margin-9.29%
EBIT Margin-22.63%
Analyst Forecast
The average price target for BioNTech SE is €120.07, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€120.07
Price Target Upside51.23% Upside
Analyst ConsensusStrong Buy
Analyst Count15
Revenue Growth Forecast―
EPS Growth Forecast―